within Pharmacolibrary.Drugs.ATC.H;

model H01CB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.009666666666666665,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0136,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Octreotide is a synthetic octapeptide and somatostatin analogue that inhibits the release of several hormones such as growth hormone and insulin. It is used clinically for the management of acromegaly, treatment of severe diarrhea and flushing associated with carcinoid tumors, vasoactive intestinal peptide tumors (VIPomas), and other neuroendocrine tumors. Octreotide is currently approved and in use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after subcutaneous administration.</p><h4>References</h4><ol><li><p>Chanson, P, et al., &amp; Harris, AG (1993). Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. <i>Clinical pharmacokinetics</i> 25(5) 375–391. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199325050-00004&quot;>10.2165/00003088-199325050-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8287633/&quot;>https://pubmed.ncbi.nlm.nih.gov/8287633</a></p></li><li><p>Gadelha, MR, et al., &amp; Frohman, LA (2012). A subcutaneous octreotide hydrogel implant for the treatment of acromegaly. <i>Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</i> 18(6) 870–881. DOI:<a href=&quot;https://doi.org/10.4158/EP11388.OR&quot;>10.4158/EP11388.OR</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22784835/&quot;>https://pubmed.ncbi.nlm.nih.gov/22784835</a></p></li><li><p>Tuvia, S, et al., &amp; Mamluk, R (2012). Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. <i>The Journal of clinical endocrinology and metabolism</i> 97(7) 2362–2369. DOI:<a href=&quot;https://doi.org/10.1210/jc.2012-1179&quot;>10.1210/jc.2012-1179</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22539587/&quot;>https://pubmed.ncbi.nlm.nih.gov/22539587</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01CB02;
